PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67

Rhea-AI Filing Summary

PharmaCyte Biotech, Inc. director Michael M. Abecassis received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036. According to the terms, the options vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Abecassis Michael M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	119,170	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 119,170 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 119,170 options Exercise price: $0.67 per share Expiration date: March 30, 2036 +2 more

5 metrics

Options granted 119,170 options Stock option grant to director on March 31, 2026

Exercise price $0.67 per share Strike price for the 119,170 underlying common shares

Expiration date March 30, 2036 Option term end for director grant

Underlying shares 119,170 shares Common stock underlying the option award

Post-grant derivative holdings 119,170 options Total derivative securities beneficially owned after transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest in full, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 0.6700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-03-30T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in full financial

"The options shall vest in full on the date of the Issuer's next annual meeting"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abecassis Michael M

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NEVADA 89169

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.67	03/31/2026		A		119,170		(1)	03/30/2036	Common Stock	119,170	$0	119,170	D

Explanation of Responses:

1. The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Jeffrey D. Cohan, as Attorney-in-Fact for Michael M. Abecassis	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Michael M. Abecassis do in this Form 4 for PMCB?

Michael M. Abecassis received a grant of stock options for 119,170 shares of PharmaCyte Biotech common stock. These options are a form of equity compensation and give him the right to buy shares at a fixed exercise price in the future.

What are the key terms of the stock options granted to Abecassis at PharmaCyte Biotech (PMCB)?

The grant covers 119,170 underlying common shares with an exercise price of $0.67 per share. The options expire on March 30, 2036, providing a long exercise window if vesting conditions tied to his continued board service are satisfied.

When do Michael Abecassis’s PharmaCyte Biotech stock options vest?

The options vest in full on the date of PharmaCyte Biotech’s next annual meeting of stockholders. Vesting is conditional on Abecassis continuing his service as a director through that date, as specified in the footnote to the Form 4.

Is this PMCB Form 4 a stock purchase or a compensation grant?

This Form 4 reports a compensation grant, not an open-market stock purchase. Abecassis received stock options with a $0.67 exercise price, meaning he did not pay cash to buy shares now but gained the right to buy in the future if he chooses.

How many PharmaCyte Biotech derivative securities does Abecassis hold after this transaction?

Following the reported transaction, Abecassis holds 119,170 stock options linked to PharmaCyte Biotech common stock. This reflects the full amount of the new grant, as indicated by the total derivative securities beneficially owned after the award on the Form 4.